Cargando…
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
BACKGROUND: The PI3K pathway is hyperactivated in many cancers, including 70 % of breast cancers. Pan- and isoform-specific inhibitors of the PI3K pathway are currently being evaluated in clinical trials. However, the clinical responses to PI3K inhibitors when used as single agents are not as effici...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820873/ https://www.ncbi.nlm.nih.gov/pubmed/27048245 http://dx.doi.org/10.1186/s13058-016-0697-1 |